# Hans J. Hammers

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hans-j-hammers/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,324 |
| Field | Renal cell carcinoma treatment |
| h-index | 62 |
| i10-index | 140 |
| Last Known Institution | Southwestern Medical Center |
| OpenAlex ID | https://openalex.org/A5103085920 |
| ORCID iD | https://orcid.org/0000-0002-6224-4559 |
| Works | 434 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.